Leucine

Leucine provides an AI-based digital platform that automates compliance management and manufacturing record creation for pharmaceutical manufacturers. The platform enables the creation of digital twins to analyze deviations, offer real-time performance monitoring, and transform paper-based data into digital format to significantly streamline the digitization process. 

Its flagship offering, the “Compliance Cloud” platform, acts as a digital twin of the pharma manufacturing shop floor. This platform is distinguished by its ability to automate compliance and improve safety in drug manufacturing through real-time performance monitoring, compliance management, and provision of actionable insights. 

The company claims its technology can reduce paper-based errors by 92%, improved batch manufacturing by 36%, and achieved 3x return on investments to its customers. 

Key customers and partnerships

The company’ key customers range from new biotechnology firms to pharmaceutical giants, including Lupin, Mylan, Viatris, Dr. Reddy’s, Pramal, and Cipla. 

The company has reportedly achieved a 100% growth in the number of facilities using their product and a 300% increase in users in 2023. As of June 2024, the company’s compliance cloud platform is used by 30+ companies in more than 350 pharmaceutical manufacturing facilities across 10 countries.

Funding and financials

In October 2023, Leucine secured USD 7 million in a Series A funding round led by Ecolab. The new funding was allocated towards enhancing Leucine's AI capabilities and expanding its reach to more facilities and customers.